The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•30 April 2026•

1 min read

AC Immune Initiates Final ABATE Trial Cohort, Triggers $12M Milestone Payment from Takeda

Key Facts

1AC Immune dosed the first patients in Cohort AD4 of the Phase 1b/2 ABATE trial for Alzheimer's disease.

2The initiation triggers a $12 million milestone payment from Takeda under an exclusive worldwide option and license agreement.

3Data from ABATE Cohorts AD1, AD2, and AD3 after 12 months of treatment is expected in Q2 2026.

AC Immune SA has officially dosed the first patients in Cohort AD4 of its Phase 1b/2 ABATE trial, targeting Alzheimer's disease. This clinical milestone triggers a $12 million payment from Takeda under their exclusive worldwide option and license agreement. The expansion into this final cohort is a key part of the strategic collaboration to evaluate the immunotherapy candidate ACI-24. According to the company's timeline, data from Cohorts AD1, AD2, and AD3 after 12 months of treatment is anticipated in the second quarter of 2026. This development provides a significant cash injection for the clinical-stage biotech firm while advancing its neurodegenerative disease pipeline. Investors remain focused on the long-term potential of the ABATE trial as it moves toward critical data readouts.